RetinalGenix Technologies Expands Patent Portfolio for Home and Remote Monitoring, Preparing for the Future of Eye and Systemic Disease Management

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Sep 25 2025

0mins

Source: Newsfilter

Patent Advancements: RetinalGenix Technologies has secured new patents for real-time home and remote ocular monitoring, enhancing its capabilities in early disease detection, particularly for conditions like diabetes and Alzheimer's disease.
Innovative Technology Integration: The company plans to integrate its DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform with high-resolution retinal imaging systems to provide patients and clinicians with actionable biomarker information, aiming to streamline care and reduce office visits.
Market Positioning: RetinalGenix's extensive patent portfolio positions it for potential partnerships and revenue growth in the telemedicine and healthcare technology sectors, emphasizing its commitment to accessible and patient-centered diagnostics.
CEO's Vision: CEO Jerry Katzman highlighted the company's goal to revolutionize eye care and systemic disease detection by providing 24/7 real-time health data access, facilitating early interventions and new care models.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.